Amivantamab

Generic name: Amivantamab
Brand names: Rybrevant
Dosage form: intravenous solution (vmjw 50 mg/mL)
Drug class: Miscellaneous antineoplastics

Usage of Amivantamab

Amivantamab is used to treat non-small cell lung cancer that has an abnormal "EGFR" gene and has spread to other parts of the body (metastatic) or cannot be removed with surgery. Your doctor will make sure you have the correct tumor type to be treated with amivantamab.

Amivantamab is given after other treatments did not work or stopped working.

Amivantamab may also be used for purposes not listed in this medication guide.

Amivantamab side effects

Get emergency medical help if you have signs of an allergic reaction (hives, difficult breathing, swelling in your face or throat) or a severe skin reaction (fever, sore throat, burning eyes, skin pain, red or purple skin rash with blistering and peeling).

Some side effects may occur during the injection. Tell your care provider if you feel nauseated, light-headed, short of breath, chilled or feverish, or if you have chest discomfort.

Amivantamab may cause serious side effects. Call your doctor at once if you have:

eye pain or redness, itching, watery eyes, sensitivity to light;

vision changes;

dark floating spots in your field of vision (floaters);

skin changes such as acne, itching, or dryness; or

lung problems (may be similar to symptoms of your cancer)--new or worsening cough, fever, or shortness of breath.

Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.

Common side effects of amivantamab may include:

a reaction during the injection;

cough, shortness of breath;

feeling very tired;

rash;

infection of the a skin around your nails;

swelling anywhere in your body;

nausea, vomiting, constipation;

mouth sores;

joint or muscle pain; or

abnormal blood tests.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking Amivantamab

Tell your doctor if you have ever had lung problems other than cancer.

May harm an unborn baby. You may need a pregnancy test to make sure you are not pregnant. Use birth control while using amivantamab and for at least 3 months after your last dose. Tell your doctor if you become pregnant.

Do not breastfeed while using this medicine, and for at least 3 months after your last dose.

Relate drugs

How to use Amivantamab

Usual Adult Dose for Non-Small Cell Lung Cancer:

Weeks 1 to 4:-Less than 80 kg: 1050 mg IV once a week for 4 doses-At least 80 kg: 1400 mg IV once a week for 4 dosesWeek 5 onwards:-Less than 80 kg: 1050 mg IV every 2 weeks-At least 80 kg: 1400 mg IV every 2 weeksDuration of therapy: Until disease progression or unacceptable toxicity.Infusion Rates for 1050 mg Dose:-Week 1 (split dose infusion):---Day 1 (350 mg dose):-----Initial rate: 50 mL/hour-----Subsequent rate: 75 mL/hour---Day 2 (700 mg dose):-----Initial rate: 50 mL/hour-----Subsequent rate: 75 mL/hour-Week 2 (1050 mg dose): 85 mL/hour-Subsequent weeks (1050 mg dose): 125 mL/hourInfusion Rates for 1400 mg Dose:-Week 1 (split dose infusion):---Day 1 (350 mg dose):-----Initial rate: 50 mL/hour-----Subsequent rate: 75 mL/hour---Day 2 (1050 mg dose):-----Initial rate: 35 mL/hour-----Subsequent rate: 50 mL/hour-Week 2 (1400 mg dose): 65 mL/hour-Week 3 (1400 mg dose): 85 mL/hour-Subsequent weeks (1400 mg dose): 125 mL/hourComments:-The dose should be based on baseline body weight; dose adjustments are not needed for subsequent body weight changes.-The initial dose should be administered as a split infusion in Week 1, on Day 1 and Day 2.-Before the initial infusion on Week 1 (Days 1 and 2), premedication should be administered to reduce the risk of infusion-related reactions.---An antihistamine and antipyretic should be administered before all infusions.---A glucocorticoid is required for Week 1 (Days 1 and 2) doses only and should be used as needed for subsequent infusions.-The initial infusion rate may be increased to the subsequent infusion rate after 2 hours without an infusion-related reaction.Use: For the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by US FDA-approved test, whose disease has progressed on/after platinum-based chemotherapy

Warnings

Amivantamab can cause skin reactions. Avoid sunlight while you are receiving amivantamab and for 2 months after your last dose.

What other drugs will affect Amivantamab

Other drugs may affect amivantamab, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use.

Popular FAQ

Rybrevant works by targeting the epidermal growth factor receptor (EGFR) exon 20 insertion mutation and MET found in adult patients with certain types of non-small cell lung cancer (NSCLC). EGFR and MET are proteins that helps cells to grow. Targeting these proteins helps to slow down cancer growth. Continue reading

Rybrevant is given as an intravenous (IV) infusion into your vein weekly for four weeks, then it is given every two weeks. Your first dose will be split into two infusions given on two consecutive days. Your healthcare provider will administer this medication. Continue reading

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.